-
Je něco špatně v tomto záznamu ?
Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants
J. Fadraersada, R. Alva-Gallegos, P. Skořepa, F. Musil, K. Mrštná, L. Javorská, K. Matoušová, LK. Krčmová, M. Paclíková, A. Carazo, M. Bláha, V. Blaha, P. Mladěnka
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
UHHK, 00179906
MH CZ - DRO
NU21J-02-00021
Czech Health Research Council
SVV 260 549
Charles University
- MeSH
- anticholesteremika terapeutické užití MeSH
- antikoagulancia * terapeutické užití farmakologie MeSH
- cholesterol krev MeSH
- dabigatran terapeutické užití farmakologie MeSH
- dospělí MeSH
- hemokoagulace * účinky léků MeSH
- hyperlipoproteinemie typ II * krev farmakoterapie MeSH
- hypolipidemika * terapeutické užití farmakologie MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- PCSK9 inhibitory MeSH
- proproteinkonvertasa subtilisin/kexin typu 9 MeSH
- rivaroxaban terapeutické užití farmakologie MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Familial hypercholesterolemia (FH) is a relatively rare genetic disease associated with high serum cholesterol levels but also with abnormalities in blood coagulation. Novel pharmacotherapeutic approaches in FH including proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9Ab) are very efficient in decreasing cholesterol levels but their impact on coagulation in FH is not yet established. Therefore, we hypothesized that these novel antidyslipidemic drugs can positively impact blood coagulation due to their more potent effect on cholesterol. A total of 15 healthy volunteers and all 15 available patients with severe FH treated at the University Hospital Hradec Králové were enrolled, coagulation was assessed by mechanic coagulometer, and the impact of four clinically used direct anticoagulants was analyzed ex vivo. FH patients were treated effectively as their total cholesterol was 4.11 ± 1.57 mM and LDL cholesterol was 2.44 ± 1.46 mM, which were even lower values than detected in our generally healthy controls. Twelve from the 15 FH patients were finally analyzed as 3 were treated with anticoagulants. Coagulation in FH patients was prolonged more extensively by dabigatran and rivaroxaban, when compared to healthy controls. Treatment with PCSK9Ab or lipid apheresis did not seem to have a significant effect on coagulation. The latter procedure however significantly decreased serum levels of one vitamin K form, MK4. Shorter coagulation time was associated with higher levels of LDL, non-HDL, and total cholesterol. Current treatment of FH seems to improve the effects of direct anticoagulants beyond known effects on LDL cholesterol levels.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015576
- 003
- CZ-PrNML
- 005
- 20250731091106.0
- 007
- ta
- 008
- 250708s2025 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00210-024-03740-1 $2 doi
- 035 __
- $a (PubMed)39751820
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Fadraersada, Jaka $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 245 10
- $a Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants / $c J. Fadraersada, R. Alva-Gallegos, P. Skořepa, F. Musil, K. Mrštná, L. Javorská, K. Matoušová, LK. Krčmová, M. Paclíková, A. Carazo, M. Bláha, V. Blaha, P. Mladěnka
- 520 9_
- $a Familial hypercholesterolemia (FH) is a relatively rare genetic disease associated with high serum cholesterol levels but also with abnormalities in blood coagulation. Novel pharmacotherapeutic approaches in FH including proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9Ab) are very efficient in decreasing cholesterol levels but their impact on coagulation in FH is not yet established. Therefore, we hypothesized that these novel antidyslipidemic drugs can positively impact blood coagulation due to their more potent effect on cholesterol. A total of 15 healthy volunteers and all 15 available patients with severe FH treated at the University Hospital Hradec Králové were enrolled, coagulation was assessed by mechanic coagulometer, and the impact of four clinically used direct anticoagulants was analyzed ex vivo. FH patients were treated effectively as their total cholesterol was 4.11 ± 1.57 mM and LDL cholesterol was 2.44 ± 1.46 mM, which were even lower values than detected in our generally healthy controls. Twelve from the 15 FH patients were finally analyzed as 3 were treated with anticoagulants. Coagulation in FH patients was prolonged more extensively by dabigatran and rivaroxaban, when compared to healthy controls. Treatment with PCSK9Ab or lipid apheresis did not seem to have a significant effect on coagulation. The latter procedure however significantly decreased serum levels of one vitamin K form, MK4. Shorter coagulation time was associated with higher levels of LDL, non-HDL, and total cholesterol. Current treatment of FH seems to improve the effects of direct anticoagulants beyond known effects on LDL cholesterol levels.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hyperlipoproteinemie typ II $x krev $x farmakoterapie $7 D006938
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a hemokoagulace $x účinky léků $7 D001777
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a antikoagulancia $x terapeutické užití $x farmakologie $7 D000925
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a hypolipidemika $x terapeutické užití $x farmakologie $7 D000960
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a dabigatran $x terapeutické užití $x farmakologie $7 D000069604
- 650 _2
- $a rivaroxaban $x terapeutické užití $x farmakologie $7 D000069552
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a PCSK9 inhibitory $7 D000091362
- 650 _2
- $a anticholesteremika $x terapeutické užití $7 D000924
- 650 _2
- $a cholesterol $x krev $7 D002784
- 650 _2
- $a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Alva-Gallegos, Raúl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Skořepa, Pavel $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic $u Department of Military Internal Medicine and Military Hygiene, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
- 700 1_
- $a Musil, František $u Department of Occupational Medicine, Faculty of Medicine in Hradec Králové, University Hospital, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Mrštná, Kristýna $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Javorská, Lenka $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Matoušová, Kateřina $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Krčmová, Lenka Kujovská $u Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Paclíková, Markéta $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Carazo, Alejandro $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic. carazofa@faf.cuni.cz
- 700 1_
- $a Bláha, Milan $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Blaha, Vladimír $u 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Mladěnka, Přemysl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- 773 0_
- $w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 398, č. 6 (2025), s. 7343-7352
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39751820 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091100 $b ABA008
- 999 __
- $a ok $b bmc $g 2366432 $s 1252701
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 398 $c 6 $d 7343-7352 $e 20250103 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
- GRA __
- $a UHHK, 00179906 $p MH CZ - DRO
- GRA __
- $a NU21J-02-00021 $p Czech Health Research Council
- GRA __
- $a SVV 260 549 $p Charles University
- LZP __
- $a Pubmed-20250708